TY - JOUR
T1 - Effect of Supervised Resistance Training on Arm Volume, Quality of Life and Physical Perfomance Among Women at High Risk for Breast Cancer-Related Lymphedema
T2 - A Study Protocol for a Randomized Controlled Trial (STRONG-B)
AU - Ramírez-Parada, Karol
AU - Lopez-Garzon, Maria
AU - Sanchez-Rojel, Cesar
AU - Petric-Guajardo, Militza
AU - Alfaro-Barra, Margarita
AU - Fernández-Verdejo, Rodrigo
AU - Reyes-Ponce, Alvaro
AU - Merino-Pereira, Gina
AU - Cantarero-Villanueva, Irene
N1 - Publisher Copyright:
Copyright © 2022 Ramírez-Parada, Lopez-Garzon, Sanchez-Rojel, Petric-Guajardo, Alfaro-Barra, Fernández-Verdejo, Reyes-Ponce, Merino-Pereira and Cantarero-Villanueva.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Objectives: To determine the preventive effects of supervised resistance training on arms volume, quality of life, physical performance, and handgrip strength in Chilean women at high risk for breast cancer-related lymphedema (BCRL) undergoing chemotherapy. Design: Randomized control trial. Participants: One hundred and six women at high risk for breast cancer-related lymphedema aged 18 to 70 years. Interventions: Participants will be randomized into two groups: [a] intervention, who will receive 12 weeks of supervised resistance training (STRONG-B) during adjuvant chemotherapy; and [b] control, who will receive education to promote lymphatic and venous return, maintain range of motion, and promote physical activity. Main Outcome Measures: The primary outcome will be arms volume measured with an optoelectric device (perometer NT1000). Secondary outcomes will be quality of life, handgrip strength, and physical performance. Primary and secondary outcomes will be measured at baseline, just after the intervention, and 3 and 6 months after. Statistical analysis will be performed following intention-to-treat and per-protocol approaches. The treatment effect will be calculated using linear mixed models. Discussion: The STRONG-B will be a tailored supervised resistance training that attempts to prevent or mitigate BCRL in a population that, due to both intrinsic and extrinsic factors, will commonly suffer from BCRL. Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT04821609], identifier NCT04821609.
AB - Objectives: To determine the preventive effects of supervised resistance training on arms volume, quality of life, physical performance, and handgrip strength in Chilean women at high risk for breast cancer-related lymphedema (BCRL) undergoing chemotherapy. Design: Randomized control trial. Participants: One hundred and six women at high risk for breast cancer-related lymphedema aged 18 to 70 years. Interventions: Participants will be randomized into two groups: [a] intervention, who will receive 12 weeks of supervised resistance training (STRONG-B) during adjuvant chemotherapy; and [b] control, who will receive education to promote lymphatic and venous return, maintain range of motion, and promote physical activity. Main Outcome Measures: The primary outcome will be arms volume measured with an optoelectric device (perometer NT1000). Secondary outcomes will be quality of life, handgrip strength, and physical performance. Primary and secondary outcomes will be measured at baseline, just after the intervention, and 3 and 6 months after. Statistical analysis will be performed following intention-to-treat and per-protocol approaches. The treatment effect will be calculated using linear mixed models. Discussion: The STRONG-B will be a tailored supervised resistance training that attempts to prevent or mitigate BCRL in a population that, due to both intrinsic and extrinsic factors, will commonly suffer from BCRL. Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT04821609], identifier NCT04821609.
KW - breast cancer lymphedema
KW - breast neoplasms
KW - physical therapy specialty
KW - quality of life
KW - resistance training
UR - http://www.scopus.com/inward/record.url?scp=85127356388&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.850564
DO - 10.3389/fonc.2022.850564
M3 - Artículo
AN - SCOPUS:85127356388
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 850564
ER -